Molecular mechanism of antitumor activity of taxanes in lung cancer (Review)

International Journal of Oncology

Volumn 27, Issue 1, 2005, Pages 247-256

  Zhao, Jinshun ^a   Kim, Jee Eun ^a   Reed, Eddie ^a   Li, Qingdi Q ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell cycle; Docetaxel; Drug resistance; Lung cancer; Paclitaxel; Taxane

Indexed keywords

ANTINEOPLASTIC AGENT; TAXOID;

APOPTOSIS; CELL CYCLE; DRUG RESISTANCE; FEMALE; HUMAN; LUNG TUMOR; MALE; METABOLISM; MICROTUBULE; MORTALITY; REVIEW; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULES; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 24644500678     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.1.247     Document Type: Review

References (128)

1. Danesi R, De Braud F, Fogli S, De Pas TM, Paolo AD, Curigliano G and Tacca MD: Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 55:57-103,2003.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Fueuer EJ and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
3. Travis WD, Travis LB and Devesa SS: Lung cancer. Cancer 75: 191-202, 1995.
4. Scagliotti GV and Turrisi AT: Docetaxel-based combinedmodality chemoradiotherapy for locally advanced non-small cell lung cancer. Oncologist 8: 361-374, 2003.
5. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC and Von Hoff DD: Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3: 121-124, 1992.
6. Roytta M, Laine KM and Harkonen P: Morphological studies on the effect of taxol on cultured human prostatic cancer cells. Prostate 11:95-106, 1987.
7. Riondel J, Jacrot M, Fessi H, Puisieux F and Potier: Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo 6: 23-27, 1992.
8. Egawa T, Kubota T, Suto A, Otani Y, Furukawa T, Saikawa Y, Watanabe M, Kumai K and Kitajima M: Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts. In Vivo 17: 23-28, 2003.
9. Horwitz SB: Personal recollections on the early development of taxol. J Nat Prod 67: 136-138, 2004.
10. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sei USA 77: 1561-1565, 1980.
11. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J Am ChemSoc 93: 2325-2327, 1971.
12. Rowinsky EK and Ross CD: Paclitaxel (taxol). N Eng J Med 332: 1004-1014, 1995.
13. Hortobagyi GN: Overview of new treatments for breast cancer. Breast Cancer Res Treat 21:3-13,1992.
14. Hortobagyi GN, Holmes FA, Theriault RL and Buzdar AU: Use of taxol (paclitaxel) in breast cancer. Oncology 51: 29-32, 1994.
15. McCloskey DE, Kaufmann SH, Prestigiacomo LJ and Davidson NE: Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. Clin Cancer Res 2: 847-854, 1996.
16. Rowinsky EK, Onetto N, Canetta RM and Arbuck SG: Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19: 646-662, 1992.
17. Nicoletti MI, Lucchini V, D'Incalci M and Giavazzi R: Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 30A: 691-696, 1994.
18. Kavanagh JJ: Docetaxel in the treatment of ovarian cancer. Oncology 16:73-81,2002.
19. Yamori T, Sato S, Chikazawa H and Kadota T: Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res 88: 1205-1210, 1997.
20. Bepler G and O'Briant K: In vitro chemosensitivity testing of human non-small cell lung cancer cell lines. Anticancer Res 18: 3181-3185,1998.
21. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T and Thatcher N: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92: 1074-1080,2000.
22. Gligorov J and Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9: 3-8, 2004.
23. Eckardt J, Eckhardt G and Hoff DV: New anticancer agents in clinical development. Oncology 9: 1321-1328, 1995.
24. Sparreboom A, van Tellingen O, Nooijen WJ and Beijnen JH: Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9: 1 -17, 1998.
25. Georgoulias V: Docetaxel (taxotere) in the treatment of nonsmall cell lung cancer. Curr Med Chem 9: 869-877, 2002.
26. Belani CP: Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol 29: 4-9, 2002.
27. Le Guen Y and Le Cesne A: Docetaxe] and non-small cell lung cancer. Bull Cancer 91: 263-270, 2004.
28. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
29. Cassidy J and Kaye SB: New drugs in clinical development in Europe. Hematol Oncol Clin North Am 8: 289-303, 1994.
30. Ramalingam S and Belani CP: Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother 3: 1693-1709, 2002.
31. Sullivan KF and Cleveland DW: Identification of conserved isotype-defining variable region sequences for four vertebrate ß-tubulin polypeptide classes. Proc Natl Acad Sei USA 83: 4327-4331, 1986.
32. Goodsell DS: The molecular perspective: microtubules and the taxanes. Stem Cells 18: 382-383, 2000.
33. De Brabander M, Geuens G, Nuydens R and Willebrords R: Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sei USA 78: 5608-5612, 1981.
34. Kumar N: Taxol-induced polymerization of purified tubulin. J Biol Chem 256: 10435-10441, 1981.
35. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
36. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sei USA 90: 9552-9556, 1993.
37. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996.
38. Yvon A-MC, Wadsworth P and Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10: 947-959, 1999.
39. Derry WB, Wilson L and Jordan MA: Substoichiometric binding of taxol suppresses dynamics. Biochemistry 21: 2203-2211, 1995.
40. Jordan MA, Thrower D and Wilson L: Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sei 102: 401-416, 1992.
41. Jordan MA and Wilson L: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130, 1998.
42. Zhai Y, Kronebusch PJ, Simon PM and Borisy GG: Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis. J Cell Biol 135: 201-214, 1996.
43. Schiff PB and Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry 20: 3247-3252, 1981.
44. Rao S, Horwitz SB and Ringel I: Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 84: 785-788, 1992.
45. Dasgupta D, Park H, Harriman GC, Georg GI and Hirnes RH: Synthesis of a photoaffinity axol analogue and its use in labeling tubulin. J Med Chem 37: 2976-2980, 1994.
46. Snyder JP, Nettles JH, Comett B, Downing KH and Nogales E: The binding conformation of Taxol in B-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sei USA 98:5312-5316,2001.
47. Waters JC, Mitchison TJ, Rieder CL and Salmon ED: The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol Biol Cell 7: 1547-1558, 1996.
48. Derry WB, Wilson L and Jordan MA: Low potency of taxol at microtubule minus ends: Implications for its antimitotic and therapeutic mechanism. Cancer Res 58: 1177-1184, 1998.
49. Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE and Sackett DL: FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 11:445-454,2000.
50. Paoletti A, Giocanti N, Favaudon V and Bornens M: Pulse treatment of interphase HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis. J Cell Sei 110: 2403-2415, 1997.
51. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME and Huang Y: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563-568, 1993.
52. Gangemi RM, Tiso M, Marchetti C, Severi AB and Fabbi M: Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 36: 385-392, 1995.
53. Li X, Gong J, Feldman E, Seiter K, Traganos F and Darzynkiewicz Z: Apoptotic cell death during treatment of leukemias. Leuk Lymphoma 13: 65-70, 1994.
54. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ and Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314, 1996.
55. Chen JG, Yang CP, Cammer M and Horwitz SB: Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63: 7891-7899, 2003.
56. Blagosklonny MV, Robey R, Sheikh MS and Fojo T: Paclitaxelinduced FasL-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther 1:113-117, 2002.
57. Yeung TK, Germond C, Chen X and Wang Z: The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 263: 398-404, 1999.
58. Suzuki A, Kawabata T and Kato M: Necessity of interleukin-lß converting enzyme cascade in taxotere-initiated death signaling. Eur J Pharmacol 343: 87-92, 1998.
59. Schimming R, Mason KA, Hunter N, Weil M, Kishi K and Milas L: Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 43: 165-172, 1999.
60. Torres K and Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58: 3620-3626, 1998.
61. Giannakakou P, Robey R, Fojo T and Blagosklonny MV: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20: 3806-3813,2001.
62. Banerjee S, Fallis AG and Brown DL: Differential effects of taxol on two human cancer cell lines. Oncol Res 9: 237-248, 1997.
63. Weigel TL, Lotze MT, Kim PK, Amoscato AA, Luketich JD and Odoux C: Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. J Thorac Cardiovasc Surg 119: 795-803, 2000.
64. Das GC, Holiday D, Gallardo R and Haas C: Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. Cancer Lett 165: 147-153, 2001.
65. Lieu CH, Chang YN and Lai YK: Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells. Biochem Pharmacol 53: 1587-1596, 1997.
66. Georgiadis MS, Russell EK, Gazdar AF and Johnson BE: Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 3:449-454,1997.
67. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (taxol) in human tumor cell lines. Br J Cancer 68: 1104-1109,1993.
68. Wang T-H, Wang H-S and Soong Y-K: Paclitaxel-induced cell death. Cancer 88: 2619-2628, 2000.
69. Long BH and Fairchild CR: Paclitaxel inhibits progression of mitotic cells to Gl phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 15: 4355-4361, 1994.
70. Chen J-G and Horwitz SB: Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 62: 1935-1938,2002.
71. Dziadyk JM, Sui M, Zhu X and Fan W: Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res 24: 27-36, 2004.
72. Woods CM, Zhu J, McQueney PA, Bollag D and Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1: 506-526, 1995.
73. Bogdan C and Ding A: Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor-a and interleukin-1 in macrophages. J Leukoc Biol 52: 119-121, 1992.
74. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality. Int J Cancer 83: 151-156, 1999.
75. Mollinedo F and Gajate C: Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8: 413-450, 2003.
76. Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G and Zunino F: Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate 48:254-264,2001.
77. Yu H: Regulation of APC-Cdc20 by the spindle checkpoint. Curr Opin Cell Biol 14: 706-714, 2002.
78. Shah JV and Cleveland DW: Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell 103: 997-1000, 2000.
79. Zhou J, Yao J and Joshi HC: Attachment and tension in the spindle assembly checkpoint. J Cell Sei 115: 3547-3555, 2002.
80. Masuda A, Maeno K, Nakagawa T, Saito H and Takahashi T: Association between mitotic spindle checkpoint impairement and susceptibility to the induction of apoptosis by antimicrotubule agents in human lung cancers. Am J Pathol 163: 1109-1116,2003.
81. Sudo T, Nitta M, Saya H and Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508, 2004.
82. Holloway SL, Glotzer M, King RW and Murray AW: Anaphase is initiated by protelysis rather than by the inactivation of maturation-promoting factor. Cell 73: 1393-1402, 1993.
83. Fang G, Yu H and Kirschner MW: Control of mitotic transitions by the anaphase-promoting complex. Phil Trans R Soc Lond 354: 1583-1590, 1999.
84. Thornton BR and Toczyski DP: Securin and B-cyclin/CDK are the only essential targets of the APC. Nat Cell Biol 5: 1090-1094, 2003.
85. Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32, 2001.
86. Clute P and Pines J: Temporal and spatial control of cyclin Bl destruction in metaphase. Nat. Cell Biol 1: 82-87, 1999.
87. Donaldson KL, Goolsby GL, Kiener PA and Wahl AF: Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5: 1041-1050, 1994.
88. Ling WH, Consoli U, Tornos C, Andreeff M and Perez-Soler R: Accumulation of cyclin Bl, activation of cyclin-Bl-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 75:925-932, 1998.
89. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ and Hung M-C: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21cipl, which inhibits p34cdc2 kinase. Mol Cell Biol 2: 581-591, 1998.
90. Makino K, Yu D and Hung M-C: Transcriptional upregulation and activation of p55Cdc via p34 (cdc2) in Taxol-induced apoptosis. Oncogene 20: 2537-2543, 2001.
91. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815,2001.
92. Andreassen PR and Margolis RL: Microtubule dependency of p34cdc2 inactivation and mitotic exit in mammalian cells. J Cell Biol 127:789-802, 1994.
93. Barboule N, Chadebech P, Baldin V, Vidal S and Valette A: Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adnocarcinoma cell line. Oncogene 15: 2867-2875, 1997.
94. Meek DW: The role of p53 in the response to mitotic spindle damage. Pathol Biol 48: 246-254, 2000.
95. Sorger PK, Dobles M, Tournebize R and Hyman AA: Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 9: 807-814, 1997.
96. Tsuiki H, Nitta M, Tada M, Inagaki M, Ushio Y and Saya H: Mechanisms of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines. Oncogene 25: 420-429,2001.
97. Salah-Eldin AE, Inoue S, Tsukamoto S, Aoi H and Tsuda M: An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment. Int J Cancer 103: 53-60, 2003.
98. Scatena CD, Stewart ZA, Mays D, Tang JL, Keefer CJ, Leach SD and Pietenpol JA: Mitotic phosphorylation of bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J Biol Chem 273: 30777-30784, 1998.
99. Ling Y-H, Tornos C and Perez-Soler R: Phosphorylation of bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 273: 18984-18991, 1998.
100. Yamamoto K, Ichijo H and Korsmeyer SJ: Bcl-2 is phosphorylated and inactivated by an ASKl/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 19: 8469-8478, 1999.
101. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
102. Basu A and Haldar S: Microtubule-damaging drugs triggered bcI2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 13: 659-664, 1998.
103. Haldar S, Basu A and Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.
104. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homology, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
105. Brady HJ and Gil-Gomez G: Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol 30: 647-650, 1998.
106. Haldar S, Jena N and Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sei USA 92: 4507-4511, 1995.
107. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS and Longo DL: Involvement of microtubules in the regulation of bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18: 3509-3517, 1998.
108. Lee L-F, Li G, Templeton DJ and Ting JP-Y: Paclitaxel (taxol)- induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273: 28253-28260, 1998.
109. Shim J, Lee H, Park J, Kim H and Choi EJ: A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381:804-806,1996.
110. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331,1995.
111. Karin M, Liu Z and Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997.
112. Wang T-H, Popp DM, Wang H-S, Saitoh M, Mural JG, Henley DC, Ichijo H and Wimalasena J: Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 274: 8208-8216, 1999.
113. Collins TS, Lee L-F and Ting JP-Y: Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-KB- and AP-1-dependent mechanism. Cancer Immunol Immunother 49: 78-84, 2000.
114. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinous J-C and Arkinstall S: Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein racl, J Biol Chem 272: 25238-25242, 1997.
115. Huisman C, Ferreira CG, Broker LE, Rodriguez JA, Smit EF, Postmus PE, Kruyt FA and Giaccone G: Paclitaxel triggers cell death primarily via caspase-independent routes in the nonsmall cell lung cancer cell line NCI-H460. Clin Cancer Res 8: 596-606, 2002.
116. Ferreira CG, Span SW, Tolis C, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM and Giaccone G: Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/AP01) signaling pathway. Clin Cancer Res 6: 203-212, 2000.
117. Strobel T, Swanson L, Korsmeyer S and Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sei USA 93: 14094-14099, 1996.
118. Lawen A: Apoptosis - an introduction. Bioessays 25: 888-896, 2003.
119. Gennann UA: P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944, 1996.
120. Van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM and Giaccone G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5: 249-255, 1998.
121. Yen JJ, Hsu WH, Wang JJ, Ho ST and Kao A: Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 70: 32-35, 2003.
122. KavaIlaris M, Kuo DY-S, Burkhart CA, Regi DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific Btubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
123. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez- Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY and Martin C: Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol 17: 1786-1793, 1999.
124. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L and Jordan MA: Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sei USA 98: 11737-11742, 2001.
125. Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres K, Orr GA and Horwitz SB: Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an a-tubulin mutation. Cancer Res 63: 1207-1213, 2003.
126. Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ and Sikic BI: Conservation of the class I ß-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 1:215-225,2002.
127. Kyu-Ho Han E, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, Rosenberg SH and Ng S: Modulation of drug resistance by a-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 36: 1565-1571, 2000.
128. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M and Saijo N: Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85: 290-297, 1994.